Lysosomal storage diseases — MCQs

Question 1: A research study evaluates three siblings with Niemann-Pick disease type C: a 6-year-old with ataxia and vertical supranuclear gaze palsy, a 10-year-old with hepatosplenomegaly and mild cognitive impairment, and a 14-year-old who is asymptomatic. Genetic testing reveals all three carry the same compound heterozygous NPC1 mutations. Fibroblast studies show similar cholesterol esterification defects and filipin staining patterns. Miglustat therapy is available. Evaluate the biological basis for phenotypic variability and optimal treatment allocation.

• A. Evaluate modifier genes, epigenetic factors, and biomarkers; treat based on individual risk stratification (Correct Answer)
• B. Treat all three immediately as genetic identity predicts identical disease course
• C. Treat only symptomatic siblings as asymptomatic carrier won't develop disease
• D. Delay all treatment until symptoms appear in the youngest to confirm diagnosis
• E. Treat the 6-year-old only as neurologic symptoms indicate blood-brain barrier dysfunction

Explanation: ***Evaluate modifier genes, epigenetic factors, and biomarkers; treat based on individual risk stratification*** - **Phenotypic discordance** in Niemann-Pick type C (NPC) despite identical genotypes suggests that **modifier genes**, **epigenetic factors**, and cellular environment dictate clinical onset and severity. - Management must be personalized because **NPC1 mutations** and **filipin staining** do not perfectly correlate with clinical progression; biomarkers like **oxysterols** or **lysosphingolipids** help guide individual risk. *Treat only symptomatic siblings as asymptomatic carrier won't develop disease* - The asymptomatic 14-year-old is not a carrier but has already been confirmed to have **compound heterozygous NPC1 mutations** and pathognomonic **filipin staining**. - This sibling has the disease and is at high risk for **late-onset neurological symptoms**, requiring proactive monitoring rather than being dismissed as a carrier. *Treat all three immediately as genetic identity predicts identical disease course* - Even with identical **NPC1 mutations**, clinical presentation varies significantly (from **supranuclear gaze palsy** to asymptomatic), meaning the disease course is not identical. - While **Miglustat** is effective, immediate treatment in asymptomatic patients is debated; therapy is typically tailored to clinical or **biomarker evidence** of progression. *Treat the 6-year-old only as neurologic symptoms indicate blood-brain barrier dysfunction* - **Miglustat** crosses the **blood-brain barrier** to inhibit **glucosylceramide synthase**, but its use is not limited based on blood-brain barrier integrity. - The 10-year-old already exhibits **hepatosplenomegaly** and **cognitive impairment**, which are clear indications for therapy to prevent further neurocognitive decline. *Delay all treatment until symptoms appear in the youngest to confirm diagnosis* - The diagnosis is already confirmed via **genetic testing** showing NPC1 mutations and **fibroblast studies** showing cholesterol defects. - Delaying treatment in already symptomatic siblings (the 6 and 10-year-olds) would allow irreversible **neuronal loss** and worsening of **ataxia**.